Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: Results from the SWEFOT trial

Annals of the Rheumatic Diseases

Volumn 75, Issue 2, 2016, Pages 356-361

  Kastbom, Alf ^a,b,f   Forslind, Kristina ^c,d   Ernestam, Sofia ^a   Geborek, Pierre ^d   Karlsson, Johan A ^d   Petersson, Ingemar F ^e   Saevarsdottir, Saedis ^a   Klareskog, Lars ^a   Van Vollenhoven, Ronald F ^a   Lundberg, Karin ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c Section of Rheumatology   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY   (Sweden)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ENOLASE; AUTOANTIBODY; CITRULLINATED PEPTIDE ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; FIBRINOGEN; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; VIMENTIN; ANTIRHEUMATIC AGENT; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; ENOLASE;

ADD ON THERAPY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; DISEASE COURSE; DRUG RESPONSE; EARLY INTERVENTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; ARTHRITIS, RHEUMATOID; BLOOD; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SWEDEN;

ANTIBODY SPECIFICITY; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOGEN; HUMANS; HYDROXYCHLOROQUINE; INFLIXIMAB; MALE; METHOTREXATE; MIDDLE AGED; PEPTIDES, CYCLIC; PHOSPHOPYRUVATE HYDRATASE; RADIOGRAPHY; SULFASALAZINE; SWEDEN; VIMENTIN;

EID: 84954395872     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205698     Document Type: Article

References (30)

1. Willemze A, Trouw LA, Toes REM, et al. The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol 2012;8:144-52.
2. Wegner N, Lundberg K, Kinloch A, et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010;233:34-54.
3. Snir O, Widhe M, von Spee C, et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis 2009;68:736-43.
4. Goules JD, Goules AV, Tzioufas AG. Fine specificity of anti-citrullinated peptide antibodies discloses a heterogeneous antibody population in rheumatoid arthritis. Clin Exp Immunol 2013;174:10-7.
5. Lundberg K, Bengtsson C, Kharlamova N, et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Ann Rheum Dis 2013;72:652-58.
6. Scherer HU, van der Woude D, Willemze A, et al. Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. Ann Rheum Dis 2011;70:1461-4.
7. Brink M, Hansson M, Mathsson L, et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum 2013;65:899-910.
8. Sokolove J, Bromberg R, Deane KD, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE 2012;7:e35296.
9. Modi S, Soejima M, Levesque MC. The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin Exp Immunol 2013;173:8-17.
10. van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012;379:1712-20.
11. van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
12. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3.
13. Saevarsdottir S, Rezaei H, Geborek P, et al. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis 2015;74:1509-14.
14. Mikuls TR, O'Dell JR, Stoner JA, et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004;50:3776-82.
15. Rönnelid J, Wick MC, Lampa J, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005;64:1744-9.
16. Böhler C, Radner H, Smolen JS, et al. Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. Ann Rheum Dis 2013;72:241-44.
17. Barra L, Bykerk V, Pope JE, et al. Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes. J Rheumatol 2013;40:1259-67.
18. Guzian M-C, Carrier N, Cossette P, et al. Outcomes in recent-onset inflammatory polyarthritis differ according to initial titers, persistence over time, and specificity of the autoantibodies. Arthritis Care Res 2010;62:1624-32.
19. da Mota LM, Santos Neto LL, Pereira IA, et al. Autoantibodies in early rheumatoid arthritis: Brasília cohort-results of a three-year serial analysis. Rev Bras Reumatol 2011;51:564-71.
20. van der Woude D, Rantapää-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010;69:1554-61.
21. Innala L, Kokkonen H, Eriksson C, et al. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008;35:1002-8.
22. Fisher BA, Plant D, Brode M, et al. Antibodies to citrullinated alpha-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis. Ann Rheum Dis 2011;70:1095-8.
23. van Beers JJ, Willemze A, Jansen JJ, et al. ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression. Arthritis Res Ther 2013;15:R140.
24. Willemze A, Bohringer S, Knevel R, et al. The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Ann Rheum Dis 2012; 71:268-74.
25. Carrier N, Cossette P, Daniel C, et al. The DERAA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies. Arthritis & Rheumatism 2009;60:698-707.
26. Mathsson L, Mullazehi M, Wick MC, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008;58:36-45.
27. Syversen SW, Goll GL, van der Heijde D, et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis 2010;69:345-1.
28. Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012;122:1791-802.
29. Scherer HU, van der Woude D, Ioan-Facsinay A, et al. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 2010;62:1620-9.
30. Suwannalai P, van de Stadt LA, Radner H, et al. Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis & Rheumatism 2012;64:1323-8.